Search

This article discusses the use of different techniques for skull base reconstruction in endoscopic pituitary surgery and their association with cerebrospinal fluid (CSF) leaks. The Hadad-Bassagasteguy nasoseptal flap (NSF) has been effective in reducing CSF leaks, but there is limited data on the appearance of different reconstruction techniques on MRI and their relationship to CSF leak rates. The study reviewed patient data and imaging to compare the vascularization patterns of free mucosal grafts (FMG) and NSF, and found that patients with NSF reconstruction had higher rates of intraoperative CSF leaks. However, there was no association between patterns of flap enhancement on MRI and CSF leaks. FMGs showed a predictable change in enhancement pattern over 3 months, while NSFs without flap enhancement at 1 week still demonstrated neovascularization without increased risk of complications. [Extracted from the article]

Background: Chimeric antigen receptor (CAR)-T cell therapies targeting glioblastoma (GBM)-associated antigens such as interleukin-13 receptor subunit alpha-2 (IL-13Rα2) have achieved limited clinical efficacy to date, in part due to an immunosuppressive tumor microenvironment (TME) characterized by inhibitory molecules such as transforming growth factor-beta (TGF-β). The aim of this study was to engineer more potent GBM-targeting CAR-T cells by countering TGF-β-mediated immune suppression in the TME., Methods: We engineered a single-chain, bispecific CAR targeting IL-13Rα2 and TGF-β, which programs tumor-specific T cells to convert TGF-β from an immunosuppressant to an immunostimulant. Bispecific IL-13Rα2/TGF-β CAR-T cells were evaluated for efficacy and safety against both patient-derived GBM xenografts and syngeneic models of murine glioma., Results: Treatment with IL-13Rα2/TGF-β CAR-T cells leads to greater T-cell infiltration and reduced suppressive myeloid cell presence in the tumor-bearing brain compared to treatment with conventional IL-13Rα2 CAR-T cells, resulting in improved survival in both patient-derived GBM xenografts and syngeneic models of murine glioma., Conclusion: Our findings demonstrate that by reprogramming tumor-specific T-cell responses to TGF-β, bispecific IL-13Rα2/TGF-β CAR-T cells resist and remodel the immunosuppressive TME to drive potent anti-tumor responses in GBM., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)